Blood homocysteine concentration and mood disorders with mixed features among patients with alcohol use disorder by Oliva, Francesco et al.
RESEARCH ARTICLE Open Access
Blood homocysteine concentration and
mood disorders with mixed features
among patients with alcohol use disorder
Francesco Oliva1*† , Maurizio Coppola2†, Raffaella Mondola3, Daniele Ascheri1, Francesco Cuniberti4,
Gabriele Nibbio1 and Rocco Luigi Picci1
Abstract
Background: Blood homocysteine concentration (BHC) is higher in patients with alcohol use disorder (AUD). Previous
studies have found a relationship between depressive symptoms severity and BHC in AUD patients and recently some
authors have found high BHC among patients with bipolar disorder, both during manic and depressive episodes and in
euthymic state. However, BHC in patients with mixed mood episode has not yet been investigated. The aim of this study
was to evaluate the BHC of patients with AUD and mixed mood episode.
Methods: A sample of AUD outpatients was assessed by Mini-International Neuropsychiatric Interview (MINI Plus): those
with a DSM-IV-TR mood disorder with mixed features were included in the MIXED group (n = 45), whereas those without
mood episode were gathered in the NO MOOD group (n = 23). Two subgroups, MIXMANIA and MIXDEPRESSION, were
formed according to the prevalence of manic or depressive symptoms, assessed by Young Mania Rating Scale (YMRS),
and Hamilton Rating Scale for Depression (HDRS). The Alcohol Use Disorder Identification Test (AUDIT) was used
to appraise the AUD. BHC was determined by High-Performance Liquid Chromatography.
Results: The MIXED group showed greater severity of both depressive (26.35 ± 9.96 vs. 4.77 ± 0.92; p < 0.001) and manic
(22.35 ± 3.30 vs. 6.14 ± 1.12; p < 0.001) symptoms, and higher BHC (28.80 ± 11.47 vs. 10.83 ± 2.81; p < 0.001), than the NO
MOOD group. BHC was strongly correlated to the HDRS, YMRS and AUDIT scores, just as HDRS was to YMRS, and AUDIT
was to both HDRS and YMRS, in the MIXED group only (p < 0.001).
The MIXDEPRESSION subgroup showed higher BHC than the MIXMANIA subgroup (Mdn = 42.96, IQR = 10.44
vs. Mdn = 19.77, IQR = 5.93; p < 0.001).
A linear regression model conducted on the MIXED group found a significant predictive value for BHC of both HDRS
(β = 0.560, t = 2.43, p = 0.026) and AUDIT (β = 0.348, t = 2.17, p = 0.044).
Conclusions: Depressive symptoms seem to be mainly implicated in the BHC elevation among patients with both
mixed features mood disorder and AUD.
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Background
Homocysteine (Hcy) is a sulphurated amino acid, derived
from ingested methionine, that has received a great deal of
attention for its role in many diseases, such as hyperten-
sion, cardiovascular disease and dementia [1, 2]. Hyperho-
mocysteinemia (HHcy) may be defined as a sustained
elevation above normal concentrations of Hcy in plasma or
serum, with the reference range being 7–15 μmol/l [3, 4].
Alcohol use disorder (AUD) is a problematic pattern of
drinking, leading to clinically significant impairment or dis-
tress, characterized by behavioral and physical symptoms,
such as withdrawal, tolerance, and craving [5].
Several authors since the early 1990s have studied the as-
sociation between HHcy and AUD, reporting both that the
increase of Hcy among AUD patients is proportional to
AUD severity and that alcohol abstinence leads to a reduc-
tion of blood homocysteine concentration (BHC) [6–11].
Furthermore, some studies have reported a higher level of
Hcy among those with AUD than among either controls or
the general population, with measurements ranging from
13 to 120 μmol/l [6, 12–18].
At first, it was postulated that the HHcy found in pa-
tients suffering from AUD was due to a low intake of fol-
ate [15, 16], but succeeding studies discovered a complex
interaction between alcohol, smoke, vitamin B6, vitamin
B12, folate, betaine and Hcy metabolism that may involve
poor absorption, hepatic uptake and retention of these nu-
trients, as well as both greater damage to the liver and an
inhibition of enzyme activity [2, 19–25].
Although the correlation between folate deficiency and
depression has been investigated since the 1960s [26, 27],
studies that included measurements of BHC alongside
vitamin status started in the 1990s [28, 29]. These studies
not only found a significant association between HHcy
and depression, regardless of vitamin status [29–33], but
also suggested a poor response to antidepressants in pa-
tients with high Hcy levels [29]. According to the meta-
analysis conducted by Almeida et al. [34], patients with
HHcy are 70% more likely to have depression, while
Refsum et al. [35] reported a doubling of the risk of having
depression for Hcy levels >15 μmol/l. Although higher
levels of Hcy are found even among patients with bipolar
disorder [36, 37], no differences between euthymic and
manic patients have been shown [38]. Conversely, the re-
lationship between Hcy levels and mixed state has not yet
been explored. Widely used definitions of mixed state
classically refer to an affective condition in which depres-
sive and manic features occur simultaneously [39–41].
Mixed state was studied in the past as a subtype of manic
or depressive episode [42–45]; this concept was narrowly
interpreted in DSM-IV, where the presence of both a full
manic and a depressive syndrome for at least one week
was required [46]. DSM-5 [5] has broadened the mixed
state notion by introducing a mixed feature specifier that
can be applied to both poles of bipolar disorder, as well as
to major depressive episodes. Specifically, the specifier
stresses the presence of at least three depressive symptoms
in the manic pole and vice versa.
The link between Hcy and mixed features seems to
have a plausible biological explanation: the Hcy func-
tions as an excitatory amino acid and leads to an in-
crease in glutammatergic neurotransmission, and thus to
a calcium influx that has neurotoxic effects [47–51]; this
could lead to instability in the affective symptomatology.
It is noteworthy, albeit less well investigated, that in-
creased serum Hcy levels have also been reported in pa-
tients with major depressive disorder characterized by
an increase in anger and hostility, and even by psychotic
symptoms [52–55].
Furthermore, major depressive disorder–AUD comor-
bidity is very frequent and seems to be more prevalent
in mixed than in non-mixed episodes [46]. Similarly,
only mixed episodes were found to be significantly asso-
ciated with AUD symptoms in patients with a primary
bipolar disorder [56].
Assuming the aforementioned relationship between
mixed state, AUD and HHcy, we aimed to evaluate
whether the BHC of AUD patients with mixed mood
episode was higher than that of AUD patients without
current episode of any mood disorder, and we also fo-
cused on the differences between mixed episodes with




All outpatients who accessed the Addiction Department
of the Azienda Sanitaria Locale CN2 (Alba, Cuneo, Italy)
between January 2014 and November 2014 requesting
treatment for AUD were invited to participate in this
cross-sectional observational study. The eligibility criter-
ion was a confirmed diagnosis of AUD under the DSM-IV
definition. The exclusion criteria were (1) diagnosis of any
current episode of mood disorder without mixed features
(mania/hypomania or a major depressive episode); or (2)
diagnosis of any other DSM-IV substance use disorder.
Therefore, patients having a positive urine-screening test
for substance abuse were also excluded.
An invitation was given at the end of the patient’s first
visit and was accompanied by comprehensive information
regarding the aims, methods, risks, and benefits of the
study. If accepted, the agreement was formalized by the pa-
tient signing a written informed consent form. A unique
identification code was assigned to each patient in order to
maintain data anonymity and patient confidentiality. All
patients agreeing to participate in the study were promptly
assessed using the Mini-International Neuropsychiatric
Interview (MINI Plus, Version 5.0.0), the Young Mania
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Rating Scale (YMRS), the Hamilton Rating Scale for De-
pression (HDRS), and the Alcohol Use Disorder Identifica-
tion Test (AUDIT). At the first visit, all patients gave a
blood sample for routine blood examination and a urine
sample for urine toxicology screening. A measurement of
total plasma Hcy concentration was included in the routine
blood examination and was carried out through the im-
proved High-Performance Liquid Chromatography (HPLC)
method developed by Sawula et al. [57].
All patients with a DSM-IV mixed episode were then
included in the MIXED group, and the others were allo-
cated to the NO MOOD group. The MIXED group was
subdivided into two subgroups (MIXMANIA and MIX-
DEPRESSION) according to the prevalence of either
manic or depressive symptoms, as assessed by the Young
Mania Rating Scale (YMRS) and the Hamilton Rating
Scale for Depression (HDRS), respectively.
Assessment tools
The MINI Plus Version 5.0.0 [58] was designed as a brief
structured interview that could be used to diagnose DSM-
IV Axis I psychiatric disorders. It has demonstrated its val-
idity and reliability in comparison to other more complex
and longer tools [59]. In the present study, the interview
was administered to the enrolled patients in order: (1) to
confirm the diagnosis of DSM-IV AUD; (2) to diagnose
DSM-IV mixed episodes; (3) to exclude patients with any
mood disorder without mixed features; and (4) to exclude
patients with any other DSM-IV substance use disorder.
The AUDITconsists of a ten-item core questionnaire and
an eight-item clinical procedure. The total score ranges
from zero to 40, is based on the questionnaire alone, and
gives a reliable estimate of the severity of alcohol use behav-
ior [60]. The international and the Italian versions of this
tool have both been verified for their good psychometric
properties [61, 62]. In this study, the questionnaire was
used as a measure of the severity of the AUD.
The HDRS [63] is a 17-item self-administered tool that
is commonly used to evaluate the severity of depressive
symptoms during a major depressive episode. The ori-
ginal five levels of severity have recently been reap-
praised among the depressed population by Zimmerman
et al. [64], who compared the HDRS total score with the
Clinical Global Impression severity index. The au-
thors proposed the following four levels of severity:
0–7 for no depression, 8–16 for mild depression, 17–
23 for moderate depression, and 24 or more for se-
vere depression.
The YMRS [65] is an 11-item, clinician-administered
tool that is commonly used to evaluate the severity of
mania. Each item offers five levels of severity. The total
score varies between zero and 60. This scale has shown
good psychometric properties [65]. A score of 20 is usu-
ally used as a clinical threshold in randomized clinical
trials evaluating the efficacy of antipsychotics on mania,
although this has not yet been validated [66].
Statistical analysis
The statistical analyses were performed using IBM SPSS
Statistics for MACOS (Version 22.0. Armonk, NY: IBM
Corporation).
Comparisons of the socio-demographic and clinical
characteristics, both between the MIXED and the NO
MOOD groups and between the MIXMANIA and MIX-
DEPRESSION groups, were carried out using Pearson’s χ2
test or Fisher’s exact test for the categorical variables, de-
pending on the expected frequencies in each group. Com-
parisons of the continuous variables were performed
using either Pearson’s independent-samples t-test or the
Mann–Whitney U test, depending on whether the vari-
ables fell into normal or non-normal distributions, which
was assessed using the Shapiro–Wilk test.
The association between the clinical scales (AUDIT,
HDRS, YMRS) and the BHC was evaluated using Pearson’s
r or Kendall’s Tau-b bivariate correlation coefficient, de-
pending on the distribution of the variables. Finally, the
clinical scales results correlated with BHC were evaluated
as predictors for BHC among the MIXED group by a
linear regression model using age, gender and the clin-
ical scales as independent variables and the BHC as the
dependent variable.
A p-value of 0.05 was used to designate statistical signifi-
cance, but p-values resulting from multiple comparisons
were adjusted using Bonferroni’s correction to control for
the family-wise error rate.
Results
Overall, 52 patients were asked to participate in the
study. However, seven patients were excluded because
they met at least one of the exclusion criteria (i.e., four
patients had a major depressive episode without mixed
features, one patient had an hypomanic episode without
mixed features, and two patients had positive urine-
screening test for cocaine). No patient refused to partici-
pate in the study.
As many as 23 out of the 45 enrolled patients (51.1%)
had a DSM-IV mixed episode and were therefore included
in the MIXED group, whereas 22 patients (48.9%) were
not having any mood episode and so were included in the
NO MOOD group.
The comparison between the MIXED and the NO
MOOD groups did not show any statistically significant
differences in socio-demographic characteristics or AUD
severity, but it revealed a greater severity of both depres-
sive and manic symptoms, and higher blood Hcy con-
centration, among the MIXED group (Table 1, Fig. 1).
Moreover, in the NO MOOD group, the scores on
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both the mood scales were seen to be under the clin-
ical threshold for severe disorder, i.e. < 20 for HMRS
[66] and <24 for MDRS [64]; the BHC fell within the
general population reference range, i.e. 7–15 μmol/l
(Table 1 and Fig. 1).
As regards the BHC for the two subgroups of the
MIXED group, the MIXDEPRESSION subgroup had
higher levels of Hcy than the MIXMANIA subgroup
(Mdn = 42.96, IQR = 10.44 vs. Mdn = 19.77, IQR = 5.93;
U = 1, p < .001; Fig. 1).
The bivariate correlation matrix built for each group
showed that BHC was strongly correlated with the
HDRS, YMRS and AUDIT scores in the MIXED group,
just as HDRS was correlated with YMRS, and AUDIT
was with both HDRS and YMRS (Table 2, p < .001). By
contrast, no significant correlations were found in the
NO MOOD group (Table 2).
All the clinical variables were strongly correlated in the
MIXED group and thus all were included as predictors in
the linear regression model. The model had a very high
explanatory rating (adjusted R2 = 0.92, F = 54.3 [5, 17],
p < .001), and it showed a significantly strong predictive
value for BHC of both HDRS (β = 0.560, t = 2.43,
p = .026) and AUDIT (β = 0.348, t = 2.17, p = .044).
Discussion
The present study confirms that the BHC of patients
with AUD and mixed episode is higher than that of pa-
tients with AUD who do not currently have mood epi-
sodes. The mean BHC among patients with AUD and
mixed mood disorder was higher than that found in
those suffering from euthymic bipolar disorder without
AUD (28.8 ± 11.47 vs. 16.43 ± 10.4, [36]).
Moreover, the mean BHC in patients with AUD and no
current mood episode was in line with that observed in
the general population, and thus lower than that found in
previous studies conducted among alcoholics, which made
no distinction between those who had a mood disorder
and those who did not [6, 12–18]. We might therefore
suggest that HHcy is not in itself a condition related to
AUD, but more exactly should be considered a com-
mon feature of patients with a co-occurrence of mood
disorder and AUD.
As regards the relationship between clinical features
and Hcy, the BHC was strongly correlated with the se-
verity of depression, mania, and alcohol abuse only in
patients with mixed features and, according to the find-
ings of the linear regression, only the severity of depres-
sive and AUD symptoms (and not that of manic
symptoms) predicted blood Hcy concentration. Further-
more, as shown by Fig. 1, it seems that the two mixed
state subgroups were well defined by blood Hcy levels:
these were significantly higher among patients having
prevalent depressive symptoms than in patients having
prevalent manic symptoms.
Therefore, looking at the findings of the present study in
the light of the results of previous studies, we might suggest
that depressive symptoms seem to be mainly implicated in
a raised BHC among patients with both a mixed features
mood disorder and AUD. It might therefore be that this
particular type of population could have a genetic vulner-
ability to suffer from both depression with mixed features
and HHcy, and that this could be triggered by alcohol abuse
severe enough to warrant a diagnosis of AUD. A similar
correlation has been proposed by some studies concerning
methylenetetrahydrofolate reductase (MTHFR) polymorph-
ism among depressive and bipolar disorders [30, 67–69] .
The most important limitations of the present study
were the sample size, which can provide enough power
only for the primary aim (the comparison between the
MIXED and the NO MOOD groups), and the absence of
a group with major depressive disorder without mixed
features (such a group would have allowed a more ap-
propriate comparison with the previous literature about
this type of population).
Table 1 Socio-demographic and clinical characteristics of patients
in the MIXED group (n = 23) vs. the NO MOOD group (n = 22)
MIXED n (%) NO MOOD n (%) χ2 /F (df) p
Sexc .914 (1) .339
male 16(69.6%) 18(81.8%)
female 7(30.4%) 4(18.2%)









Employmenta .02 (1) .894
unemployed 10(43.5%) 10(43.5%)
employed 13(27.7%) 12(44.9%)
Mean(±SD) Mean(±SD) t/U (df) p
Agec 45.9(±10.49) 45.8(±10.9) .97(43) .337
HDRSd 26.35(±9.96) 4.77(±0.92) 0(43) < .001*
YMRSd 22.35(±3.30) 6.14(±1.12) 0(43) < .001*
Homocysteined 28.80(±11.47) 10.83(±2.81) 4(43) < .001*





*Statistically significant, Bonferroni corrected p < 0.005
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On the other hand, this is the first study evaluating
BHC among AUD outpatients with a mood disorder
with mixed features, and it suggests that further studies
should be undertaken to investigate the possible predispos-
ition of some AUD patients to suffer from mood disorders
(especially those with mixed features) and HHcy, stressing
also the possible role of the integration of nutrients (e.g.
folate, vitamin B6, vitamin B12, betaine, etc.) in the treat-
ment of mood disorders with AUD.
Future studies focusing on the assessment of the BHC
of patients with bipolar disorder during the different
stages of their illness are required, with close attention
being given to whether or not AUD is present.
Conclusions
To the best of our knowledge, this is the first study evaluat-
ing BHC among AUD outpatients having a mood disorder
with mixed features and it suggests that HHcy is not in it-
self a condition related to AUD but that it should be con-
sidered a common feature of patients with a co-occurrence
of mood disorder and AUD. Furthermore, depressive
symptoms seem to be mainly implicated in the higher
BHC among patients with both a mixed features mood dis-
order and AUD.
Further studies may be focused on the predisposition
to develop HHcy in patients with comorbid mood and
alcohol disorders.
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